Penumbra, Inc. (PEN)

Market Cap	10.31B
Revenue (ttm)	847.13M
Net Income (ttm)	-2.00M
Shares Out	38.18M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	277.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	278,274
Open	267.21
Previous Close	266.17
Day's Range	264.77 - 270.70
52-Week Range	114.87 - 274.71
Beta	0.52
Analysts	Buy
Price Target	297.23 (+10.06%)
Earnings Date	May 2, 2023

About PEN

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 3,800
• Stock Exchange: NYSE
• Ticker Symbol: PEN

Analyst Forecast

According to 16 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $297.23, which is an increase of 10.06% from the latest price.

Price Target

$297.23

(10.06% upside)

Analyst Consensus: Buy